Critical Limb Ischemia (CLI) Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent and Other Developments

Critical limb ischemia (CLI) is a severe peripheral arterial disease (PAD) characterised by blockage in the arteries of the lower limbs, which in turn reduces blood-flow. The primary cause of the disease is atherosclerosis or the buildup of fatty deposits called plaque in the arteries. Other risk factors for the disease include hypercholesterolemia, obesity, smoking, hypertension and diabetes. Diabetes is a significant risk factor because it is often linked with severe PADs. The most common symptoms of CLI are the ischemic rest pain — extreme pain or hard to heal sores on the feet or legs. CLI is associated with high risk for cardiovascular events, including myocardial infarction and in some cases death due to CLI. Auscultation, ankle-brachial index (ABI), magnetic resonance angiography (MR angiography), doppler ultrasound, CT angiography and angiogram are some of the tools to diagnose CLI. Treatment of the disease include medications for pain relief, endovascular treatments such as angioplasty, stents, laser atherectomy, directional atherectomy and surgical treatments such as amputation of the limb.

Explore Report at: www.psmarketresearch.com/market-analysis/critical-limb-ischemia-therapeutics-pipeline-analysis

Considerable growth is expected in the therapeutics pipeline for CLI in the near future mainly due to rising old-age population, increasing incidence of CLI and its risk factors such as diabetes and obesity. Increasing investment by companies for the research and development of drug candidates for the treatment of CLI is also a major factor driving the growth of pipeline of CLI therapeutics, globally. Lack of an approved treatment for the disease is one of the key factors encouraging companies to invest in the research and development of therapeutics for the treatment of CLI.

Request for Table of Content at: www.psmarketresearch.com/market-analysis/critical-limb-ischemia-therapeutics-pipeline-analysis/toc-sample

Recently, Rexgenero Limited received confirmation from the European Medicines Agency (EMA) to accept the design of two confirmatory Phase III clinical trials for its drug candidate, Rexmyelocel-T, in patients with CLI. Additionally, Rejuveinix by Reven Pharmaceuticals, Inc. is also in Phase I/II stage of development for the treatment of CLI.

Browse Other Related Report at: www.psmarketresearch.com/industry-report/pharmaceuticals

Some of the major players involved in the development of drugs for CLI include Caladrius Biosciences, Inc., Boston Scientific Corporation, Rexgenero Limited, Reven Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma Corporation, Anesiva, Inc., Taiwan Bio Therapeutics Co., Ltd., Beike Biotech India Pvt. Ltd., Pharmicell Co., Ltd., United Therapeutics Corporation, Stempeutics Research Pvt. Ltd.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
Kundan
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.